Ayham Ashkar, MD
Medical Oncology · Royal Oak, MINPI 1417084799
Payments from drug & device makers
Across 96 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AVEO Pharmaceuticals, Inc.$230
- Pfizer$195
- Amgen$179
- Genentech USA, Inc.$163
- Johnson & Johnson$136
- GSK$122
- plus $1K from 25 others
What the payments were for
- Food & beverage$1,82590%
- Education$20910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AVEO Pharmaceuticals, Inc. | 10 | $230 |
| Pfizer | 13 | $195 |
| Amgen | 8 | $179 |
| Genentech USA, Inc. | 8 | $163 |
| Johnson & Johnson | 2 | $136 |
| GSK | 1 | $122 |
| Gilead(2 entities) | 6 | $100 |
| Merck | 2 | $98 |
| AstraZeneca | 6 | $91 |
| Mirati Therapeutics, Inc. | 5 | $85 |
| Seagen Inc. | 5 | $80 |
| Sanofi | 2 | $61 |
| E.r. Squibb & Sons, L.L.C. | 2 | $55 |
| Novartis | 3 | $51 |
| Bristol Myers Squibb | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Tesaro, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 2 | $27 |
| Taiho Oncology, Inc. | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Morphosys, US Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Beigene USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $13 |
| Fortovia Therapeutics, Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Penumbra, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$122
How this compares
$2,034 in reported general payments places this provider in the 25th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 37 | $864,663 |
| CalquenceAcalabrutinib Maleate | 54 | $800,164 |
| XtandiEnzalutamide | 58 | $714,048 |
| JakafiRuxolitinib Phosphate | 59 | $705,939 |
| RevlimidLenalidomide | 29 | $497,465 |
| IbrancePalbociclib | 26 | $414,348 |
| ImbruvicaIbrutinib | 25 | $379,915 |
| PromactaEltrombopag Olamine | 24 | $323,387 |
| Lenalidomide | 22 | $300,343 |
| TagrissoOsimertinib Mesylate | 13 | $218,528 |
| AlunbrigBrigatinib | 11 | $211,016 |
| BrukinsaZanubrutinib | 15 | $195,920 |
| DopteletAvatrombopag Maleate | 13 | $165,035 |
| LynparzaOlaparib | 11 | $87,875 |
| EliquisApixaban | 117 | $72,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso, Lynparza | $91 | $1,106,56778 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $55 | $864,66337 claims |
| Astellas Pharma US IncXtandi | $27 | $714,04858 claims |
| Bristol Myers SquibbRevlimid | $47 | $497,46529 claims |
| PfizerIbrance, Eliquis | $195 | $486,498143 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $38 | $379,91525 claims |
| NovartisPromacta | $51 | $323,38724 claims |
| Beigene USA, Inc.Brukinsa | $16 | $195,92015 claims |
| Johnson & JohnsonXarelto | $136 | $45,04671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Royal Oak
- Patricia Lo RussoDetroit$24.6M
- Manish SharmaGrand Rapids$19M
- Moshe TalpazAnn Arbor$13.7M
- Shirish GadgeelDetroit$11M
- Zachery ReichertAnn Arbor$10.6M
- Ammar SukariDetroit$8.4M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Emerson LimGrand Rapids$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.